Literature DB >> 8407083

Intralesional treatment of cutaneous leishmaniasis with sodium stibogluconate antimony.

R M Faris1, J S Jarallah, T A Khoja, M J al-Yamani.   

Abstract

BACKGROUND: Cutaneous leishmaniasis represents a difficult disease to manage in endemic areas. Systemic treatment is hampered by both expense and compliance. Side effects may play a major role in this aspect as well.
METHODS: The effectiveness of intralesional treatment of leishmaniasis was investigated. Seven hundred and ten patients were treated with injections of sodium stibogluconate intralesionally. The clinical diagnosis was confirmed by demonstrating the parasite in the smears obtained from the lesion. Fine insulin needle was used to infiltrate the lesion with sodium stibogluconate (0.5 to 1.0 mL).
RESULTS: Generally eight injections were sufficient, but some of the complicated lesions needed up to 24 injections. Sixty-two percent of patients were men. The majority of the study population (64%) were children below 15 years of age. The results showed that 72% of lesions healed completely, 23.9% showed some improvement, while 4.1% showed some deterioration. Lesions of the lips, cheeks, chin, and neck healed faster than lesions in other parts of the body. Side effects were mild and limited to pain at the site of the injection and hyperpigmentation in those who were treated by folk medicine.
CONCLUSIONS: Intralesional treatment is as effective as the standard systemic antimonials. It offers a less expensive alternative and a low side effects profile. Our findings confirmed the findings of earlier workers. It is recommended for treatment of cutaneous leishmaniasis in endemic areas.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8407083     DOI: 10.1111/j.1365-4362.1993.tb05044.x

Source DB:  PubMed          Journal:  Int J Dermatol        ISSN: 0011-9059            Impact factor:   2.736


  9 in total

1.  Skin uptake, distribution, and elimination of antimony following administration of sodium stibogluconate to patients with cutaneous leishmaniasis.

Authors:  M al Jaser; A el-Yazigi; M Kojan; S L Croft
Journal:  Antimicrob Agents Chemother       Date:  1995-02       Impact factor: 5.191

Review 2.  [Cutaneous leishmaniasis].

Authors:  C D Enk; K Gardlo; M Hochberg; A Ingber; T Ruzicka
Journal:  Hautarzt       Date:  2003-04-18       Impact factor: 0.751

3.  [Photodynamic therapy of cutaneous leishmaniasis. A promising new therapeutic modality].

Authors:  K Gardlo; S Hanneken; T Ruzicka; N J Neumann
Journal:  Hautarzt       Date:  2004-04       Impact factor: 0.751

4.  Comparison of intralesional two percent zinc sulfate and glucantime injection in treatment of acute cutaneous leishmaniasis.

Authors:  Masoud Maleki; Gholamreza Karimi; Mohsen Tafaghodi; Somayyeh Raftari; Yalda Nahidi
Journal:  Indian J Dermatol       Date:  2012-03       Impact factor: 1.494

5.  Localised leishmaniasis of oral mucosa: report of an unusual clinicopathological entity.

Authors:  Deepak Passi; Sarang Sharma; Shubharanjan Dutta; Chandan Gupta
Journal:  Case Rep Dent       Date:  2014-09-29

6.  Species-directed therapy for leishmaniasis in returning travellers: a comprehensive guide.

Authors:  Caspar J Hodiamont; Piet A Kager; Aldert Bart; Henry J C de Vries; Pieter P A M van Thiel; Tjalling Leenstra; Peter J de Vries; Michèle van Vugt; Martin P Grobusch; Tom van Gool
Journal:  PLoS Negl Trop Dis       Date:  2014-05-01

7.  Evaluation of the Interventional Approaches in the Management of Cutaneous Leishmaniasis in Jazan: An Observational Study.

Authors:  Hafiz A Makeen; Mohammed A Buraik; Santhosh Joseph Menachery; Khalid M Alattas; Abdulkarim M Meraya
Journal:  Ann Dermatol       Date:  2018-08-28       Impact factor: 1.444

8.  Combination of topical liposomal amphotericin B and Glucantime in comparison with glucantime alone for the treatment of anthroponotic cutaneous leishmaniasis (ACL) caused by Leishmania tropica: study protocol for a randomized, controlled trial.

Authors:  Seyed Ebrahim Eskandari; Ali Khamesipour; Mahmoud Reza Jaafari; Amir Javadi; Akram Miramin Mohammadi; Hossein Keshavarz Valian; Mansour Nassiri-Kashani; Vahid Mashayekhi Goyonlo; Alireza Firooz
Journal:  Iran J Microbiol       Date:  2021-10

9.  Efficacy of intra-lesional injections of meglumine antimoniate once a week vs. twice a week in the treatment of cutaneous leishmaniasis caused by L. tropica in Iran: A randomized controlled clinical trial.

Authors:  Amir Javadi; Ali Khamesipour; Mohammad Ghoorchi; Mahdieh Bahrami; Alireza Khatami; Iraj Sharifi; Seyed Ebrahim Eskandari; Alireza Fekri; Mohamad Reza Aflatoonian; Alireza Firooz
Journal:  PLoS Negl Trop Dis       Date:  2022-07-08
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.